Overview

A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

Status:
COMPLETED
Trial end date:
2024-03-18
Target enrollment:
Participant gender:
Summary
To Evaluate the Tolerability and Pharmacokinetics of LW231 Tablets in Single-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Single-dose, Multiple-dose Phase Ia Clinical Trials in Healthy Subjects .
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Longwood Biopharmaceuticals Co., Ltd.